{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:35:58Z","timestamp":1786365358725,"version":"build-2736575974"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cellular therapies have transformed the treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL), which typically does not respond well to salvage chemotherapy. Recently, approximately 40% of r\/r DLBCL patients across three different trials achieved a complete remission at 1 year after receiving treatment with autologous chimeric antigen receptor (CAR) T cells (auto-CARs). These successes have prompted studies of auto-CARs in second-line settings, in which axicabtagene ciloleucel and lisocabtagene maraleucel both showed improved event-free survival over autologous hematopoietic cell transplantation (AHCT). While encouraging, this data also highlights that 60% of patients relapse or progress following treatment with auto-CARs. Individual disease characteristics and logistical challenges of cell engineering also limit patients\u2019 eligibility for auto-CARs. Allogeneic CAR T cells (allo-CARs) may address some of these limitations as they may mitigate delays associated with auto-CARs, thereby reducing the need for bridging chemotherapies and increasing availability of cellular products for patients with aggressive lymphomas. By being sourced from healthy donors who have never been exposed to cytotoxic chemotherapy, allo-CARs can be created from T cells with better fitness. Allo-CARs made from specific cellular subsets (e.g., stem cell memory or na\u00efve\/early memory T cells) may also have increased efficacy and long-term persistence. Additionally, allo-CARs have been successfully created from other cell types, including natural killer cells, gamma-delta T-cells and induced pluripotent stem cells. These cell types can be engineered to target viral antigens, enabling precision targeting of virally driven DLBCL. As allogeneic donor cells can be banked and cryopreserved in batches, they can be made more readily available, potentially reducing logistical hurdles and costs compared to engineering auto-CARs. This may ultimately create a more sustainable platform for cell therapies. Challenges with allo-CARs that will need to be addressed include graft versus host disease, alloimmunization, potentially decreased persistence relative to auto-CARs, and antigen escape. In short, the adaptability of allo-CARs makes them ideal for treating patients with r\/r DLBCL who have progressed through standard chemotherapy, AHCT, or auto-CARs. Here, we review the published literature on patients with r\/r DLBCL treated with allogeneic CAR products manufactured from various cell types as well as forthcoming allogeneic CAR technologies.<\/jats:p>","DOI":"10.3389\/fimmu.2022.887866","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T08:16:39Z","timestamp":1652861799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed\/Refractory DLBCL"],"prefix":"10.3389","volume":"13","author":[{"given":"Nikeshan","family":"Jeyakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study","volume":"131","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene Maraleucel (Liso-Cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) With Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2l) Treatment in Patients (Pts) With Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results From the Randomized Phase 3 Transform Study","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-Year Outcomes for Refractory B-Cell Lymphomas With CAR T-Cell Therapy","volume":"384","author":"Chong","year":"2021","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006245","article-title":"Outcomes of Patients With Large B-Cell Lymphoma Progressing After Axicabtagene Ciloleucel Therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic Transplant and CAR-T Therapy After Autologous Transplant Failure in DLBCL: A Noncomparative Cohort Analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive Factors of Early Progression After CAR T-Cell Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High Metabolic Tumor Volume is Associated With Decreased Efficacy of Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-Of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant Chimeric Antigen Receptor Therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-Derived CD19-Targeted T Cells Cause Regression of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721","article-title":"Phase I Trials Using Sleeping Beauty to Generate CD19-Specific CAR T Cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified Process for the Production of Anti-CD19-CAR-Engineered T Cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17121","article-title":"Chimeric Antigen Receptor T-Cell Therapy After Allogeneic Stem Cell Transplant for Relapsed\/Refractory Large B-Cell Lymphoma","volume":"192","author":"Lutfi","year":"2021","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity With Diminished Graft-Versus-Host Activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17186","article-title":"Chimeric Antigen Receptor (CAR) Natural Killer (NK)-Cell Therapy: Leveraging the Power of Innate Immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00900","article-title":"Invariant Natural Killer T Cells As Suppressors of Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation","volume":"8","author":"Mavers","year":"2017","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced Anti-Lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1329","article-title":"Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects Through Host CD8 T-Cell Cross-Priming","volume":"27","author":"Simonetta","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nri2781","article-title":"Gammadelta T Cell Effector Functions: A Blend of Innate Programming and Acquired Plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-Targeted Gammadelta T Cells Exhibit Innate and Adaptive Antitumor Activities in Preclinical B-Cell Lymphoma Models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical Applications of Gamma Delta T Cells With Multivalent Immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2678","article-title":"Generation of Tumor-Targeted Human T Lymphocytes From Induced Pluripotent Stem Cells for Cancer Therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00528-6","article-title":"Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges","volume":"14","author":"Nianias","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-Specific T Cells Maintain Remissions of T- and B-Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.bbmt.2019.12.590","article-title":"Durable Remission Following \u201cOff-The-Shelf\u201d Chimeric Antigen Receptor (CAR) T-Cells in Patients With Relapse\/Refractory (R\/R) B-Cell Malignancies","volume":"26","author":"Curran","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Naive T-Cell Deficits at Diagnosis and After Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T Memory Stem Cells in Health and Disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy of Chronic Lymphocytic Leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for New CAR-Based Therapies With a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race Against Cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02324","article-title":"Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues","volume":"9","author":"Castriconi","year":"2018","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK Cells and Cancer: You can Teach Innate Cells New Tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The Hypoxic Tumour Microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT Cells With Chimeric Antigen Receptor Provide a Novel Platform for Safe and Effective Cancer Immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124904","article-title":"Long-Term Outcomes of Subjects With Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated With Tabelecleucel on an Expanded Access Program","volume":"134","author":"Prockop","year":"2019","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147226","article-title":"Overall Survival By Best Overall Response With Tabelecleucel in Patients With Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant","volume":"138","author":"Prockop","year":"2021","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor Burden, Inflammation, and Product Attributes Determine Outcomes of Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering Effects of Chemotherapy on Mature T Cells Impair Proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 Studies of Central Memory-Derived CD19 CAR T-Cell Therapy Following Autologous HSCT in Patients With B-Cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric Antigen Receptor-Modified T Cells Derived From Defined CD8+ and CD4+ Subsets Confer Superior Antitumor Reactivity In Vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s Lymphoma With a Defined Ratio of CD8+ and CD4+ CD19-Specific Chimeric Antigen Receptor-Modified T Cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1002\/acg2.86","article-title":"Toward \u201cOff-the-Shelf\u201d Allogeneic CAR T Cells","volume":"3","author":"Aftab","year":"2020","journal-title":"Adv Cell Gene Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC Locus With CRISPR\/Cas9 Enhances Tumour Rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR Into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4431","article-title":"Human CD62L- Memory T Cells are Less Responsive to Alloantigen Stimulation Than CD62L+ Naive T Cells: Potential for Adoptive Immunotherapy and Allodepletion","volume":"104","author":"Foster","year":"2004","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive Assessment of T-Cell Receptor Beta-Chain Diversity in Alphabeta T Cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00307","article-title":"Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation","volume":"7","author":"Morin-Zorman","year":"2016","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular Remission of Infant B-ALL After Infusion of Universal TALEN Gene-Edited CAR T Cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of Resistance to CAR T Cell Therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-1631","article-title":"Abstract 1631: T Cell Dysfunction in Pediatric Cancer Patients at Diagnosis and After Chemotherapy can Limit Chimeric Antigen Receptor Potential","volume":"78","author":"Das","year":"2018","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early Memory Phenotypes Drive T Cell Proliferation in Patients With Pediatric Malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2155-7","article-title":"Induction of a Central Memory and Stem Cell Memory Phenotype in Functionally Active CD4(+) and CD8(+) CAR T Cells Produced in an Automated Good Manufacturing Practice System for the Treatment of CD19(+) Acute Lymphoblastic Leukemia","volume":"67","author":"Blaeschke","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of Clinical-Grade CD19-Specific CAR-Modified CD8+ Memory Stem Cells for the Treatment of Human B-Cell Malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115351","article-title":"Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function But Shorter Persistence and Less Memory-Like Phenotypes","volume":"132","author":"Kotani","year":"2018","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117493","article-title":"Starting T Cell and Cell Product Phenotype Are Associated With Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential Loss of Tumor Surface Antigens Following Chimeric Antigen Receptor T-Cell Therapies in Diffuse Large B-Cell Lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24594","article-title":"Repeated Loss of Target Surface Antigen After Immunotherapy in Primary Mediastinal Large B Cell Lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e001150","DOI":"10.1136\/jitc-2020-001150","article-title":"Point Mutation in CD19 Facilitates Immune Escape of B Cell Lymphoma From CAR-T Cell Therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T Cells With Dual Targeting of CD19 and CD22 in Adult Patients With Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of Target Antigen Density Improves CAR T-Cell Functionality and Persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.049155","article-title":"The Cytotoxicity of Anti-CD22 Immunotoxin is Enhanced by Bryostatin 1 in B-Cell Lymphomas Through CD22 Upregulation and PKC-betaII Depletion","volume":"97","author":"Biberacher","year":"2012","journal-title":"Haematologica"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-Cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-Shelf\u2019 Allogeneic CAR T Cells: Development and Challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.887866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T08:16:42Z","timestamp":1652861802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.887866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2022.887866"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.887866","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"887866"}}